Joseph Tuscano

Title(s)Professor, MED: Int Med HMCTBMT
SchoolSchool of Medicine
AddressCancer Ctr, 4501 X Street, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 2025 Jan 01; 110(1):142-152. Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. PMID: 39021209; PMCID: PMC11694104.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    2. A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2025 May; 66(5):961-964. Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J. PMID: 39731545.
      View in: PubMed   Mentions:    Fields:    
    3. Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma. Front Oncol. 2024; 14:1481950. Esteghamat N, Tsumura A, Marquez-Arreguin G, Tuscano J. PMID: 39502312; PMCID: PMC11534736.
      View in: PubMed   Mentions:
    4. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 10 17; 391(15):1379-1389. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. PMID: 39413375; PMCID: PMC11488644.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    5. Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo. Int J Mol Sci. 2024 Jul 18; 25(14). Meckler JF, Levis DJ, Kong Y, O'Donnell RT, Vang DP, Tuscano JM. PMID: 39063110; PMCID: PMC11277024.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities. PET Clin. 2024 Oct; 19(4):495-504. Mingels C, Nalbant H, Sari H, Godinez F, Sen F, Spencer B, Esteghamat NS, Tuscano JM, Nardo L. PMID: 38969563; PMCID: PMC11433941.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma. Oncologist. 2024 Apr 04; 29(4):278-288. Durando M, Gopal AK, Tuscano J, Persky D. PMID: 38207010; PMCID: PMC10994254.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 11; 21(11):1118-1131. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. PMID: 37935098.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    9. Checkpoint inhibition in hematologic malignancies. Front Oncol. 2023; 13:1288172. Tsumura A, Levis D, Tuscano JM. PMID: 37920162; PMCID: PMC10619902.
      View in: PubMed   Mentions: 4  
    10. A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo. Curr Issues Mol Biol. 2023 Aug 25; 45(9):7087-7096. Levis DJ, Meckler JF, O'Donnell RT, Tuscano JM. PMID: 37754232; PMCID: PMC10530145.
      View in: PubMed   Mentions: 1     Fields:    
    11. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2023 10; 58(10):1143-1145. Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J. PMID: 37391654.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML. Leuk Res Rep. 2023; 19:100374. Jonas BA, Potter LA, Galkin M, Tuscano JM. PMID: 37363050; PMCID: PMC10285270.
      View in: PubMed   Mentions: 3  
    13. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):749-756. Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. PMID: 37336714.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model. Cancer Immunol Immunother. 2023 Sep; 72(9):2939-2948. Meckler JF, Levis DJ, Vang DP, Tuscano JM. PMID: 37247022; PMCID: PMC10412491.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    15. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. Clin Cancer Res. 2023 05 15; 29(10):1869-1878. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. PMID: 36826995; PMCID: PMC10716864.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    16. Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy. Leuk Res. 2022 11; 122:106947. Fisch SC, Tuscano JM, Qi L, Jonas BA. PMID: 36108426.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 08; 119:106885. Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 35738024.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094. Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. PMID: 34162178; PMCID: PMC9052913.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    20. Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study. BMC Med. 2022 04 26; 20(1):165. Poh C, McPherson JD, Tuscano J, Li Q, Parikh-Patel A, Vogel CFA, Cockburn M, Keegan T. PMID: 35468782; PMCID: PMC9040269.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    21. KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. Commun Biol. 2021 12 02; 4(1):1330. Shimoda M, Lyu Y, Wang KH, Kumar A, Miura H, Meckler JF, Davis RR, Chantarasrivong C, Izumiya C, Tepper CG, Nakajima KI, Tuscano J, Barisone G, Izumiya Y. PMID: 34857874; PMCID: PMC8639922.
      View in: PubMed   Mentions: 5  Translation:HumansCells
    22. Orbital Rosai-Dorfman Disease Presenting as Optic Neuritis. J Neuroophthalmol. 2022 03 01; 42(1):e293-e296. Virk HS, Shahlaie K, Ramani B, Perry A, Fragoso R, Tuscano J, Liu YA. PMID: 35475853.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 11; 19(11):1218-1230. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. PMID: 34781267.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    24. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 01; 63(1):231-234. Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. PMID: 34486920.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021 12; 56(12):2975-2980. Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Abedi M. PMID: 34471239; PMCID: PMC8636264.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    26. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 09 01; 27(17):4726-4736. Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. PMID: 34088724; PMCID: PMC9262142.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    27. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021; 11:649209. Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 33777810; PMCID: PMC7991747.
      View in: PubMed   Mentions: 26  
    28. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e611-e618. Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. PMID: 33811007.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 04 01; 96(4):E114-E117. Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. PMID: 33476436.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    30. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):345-354.e4. Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J. PMID: 33563582.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):139-146. Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. PMID: 33478921.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    32. Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia. J Hematol. 2020 Sep; 9(3):79-83. Tuscano J, Poh C, Rosenberg A, Jonas B, Abedi M, Barisone G, Schwab E, Lundeberg K, Kaesberg P. PMID: 32855756; PMCID: PMC7430864.
      View in: PubMed   Mentions: 1  
    33. Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies. JAMA Netw Open. 2020 05 01; 3(5):e204787. Frankel PH, Chung V, Tuscano J, Siddiqi T, Sampath S, Longmate J, Groshen S, Newman EM. PMID: 32401317; PMCID: PMC7221509.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    34. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Acta Haematol. 2021; 144(1):95-99. Poh C, Arora M, Ghuman S, Tuscano J. PMID: 32348994.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):453-458. Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. PMID: 32171691; PMCID: PMC8530379.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    36. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. PMID: 31271459; PMCID: PMC6848909.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    37. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clin Cancer Res. 2019 12 01; 25(23):7004-7013. Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM. PMID: 31481504; PMCID: PMC7354236.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    38. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 11; 94(11):E291-E294. Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. PMID: 31379016.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    39. A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth. Cancers (Basel). 2019 Apr 27; 11(5). Vogel CFA, Ishihara Y, Campbell CE, Kado SY, Nguyen-Chi A, Sweeney C, Pollet M, Haarmann-Stemmann T, Tuscano JM. PMID: 31035533; PMCID: PMC6563059.
      View in: PubMed   Mentions: 24  
    40. Infectious risks associated with medicinal Cannabis: Potential implications for immunocompromised patients? J Infect. 2018 05; 76(5):500-501. McHardy I, Romanelli A, Harris LJ, Opp G, Gaudino R, Torres A, Polage CR, Tuscano JM, Thompson GR. PMID: 29408325.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation. PLoS One. 2018; 13(1):e0190860. Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM. PMID: 29304125; PMCID: PMC5755921.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    42. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017 09 08; 7(9):e605. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA. PMID: 28885611; PMCID: PMC5709750.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    43. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct; 92(10):E575-E583. Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. PMID: 28699256; PMCID: PMC6896320.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    44. A microbiome assessment of medical marijuana. Clin Microbiol Infect. 2017 04; 23(4):269-270. Thompson GR, Tuscano JM, Dennis M, Singapuri A, Libertini S, Gaudino R, Torres A, Delisle JM, Gillece JD, Schupp JM, Engelthaler DM. PMID: 27956269.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    45. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2017 05; 58(5):1254-1257. Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N. PMID: 27701909; PMCID: PMC5457839.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    46. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. PMID: 27650362; PMCID: PMC5360527.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    47. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 10; 65(10):1169-75. Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. PMID: 27506529; PMCID: PMC7643839.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    48. Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. J Drugs Dermatol. 2016 Aug 01; 15(8):1024-5. Petukhova TA, Tartar DM, Mayo K, Fung MA, Tuscano J, Jagdeo J. PMID: 27538006.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. Mol Med. 2016 Oct; 22:632-642. Satake N, Duong C, Yoshida S, Oestergaard M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Chung J, Nolta J, Nitin N, Tuscano JM. PMID: 27455414; PMCID: PMC5082301.
      View in: PubMed   Mentions: 20     Fields:    
    50. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016 Aug; 7(4):209-21. Arora M, Gowda S, Tuscano J. PMID: 27493711; PMCID: PMC4959641.
      View in: PubMed   Mentions: 16  
    51. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma. 2016 10; 57(10):2307-14. Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM. PMID: 26895565; PMCID: PMC4969190.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    52. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov; 171(4):530-8. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. PMID: 26343802; PMCID: PMC4881845.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    53. Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. Mol Med. 2015 Nov; 21(1):824-832. Kong Y, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. PMID: 26322845; PMCID: PMC4818262.
      View in: PubMed   Mentions: 4     Fields:    
    54. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10; 33(17):1936-42. Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. PMID: 25897153; PMCID: PMC4451176.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    55. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014 Nov; 167(4):487-99. Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, Rocke DM, Nolta J, Nitin N. PMID: 25196579; PMCID: PMC4212003.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    56. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. Leuk Res. 2014 Nov; 38(11):1320-6. Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM. PMID: 25241275.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    57. Adverse health effects of marijuana use. N Engl J Med. 2014 08 28; 371(9):878-9. Thompson GR, Tuscano JM. PMID: 25162901.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    58. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(4):466-77. Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC, LUCID trial investigators. PMID: 25130401.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    59. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May; 165(3):375-81. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. PMID: 24606326.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    60. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May; 165(4):510-8. Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. PMID: 24579926.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    61. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct; 55(10):2301-4. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM. PMID: 24369094; PMCID: PMC4143479.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    62. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014 Apr-May; 13(4-5):560-4. Bass GF, Tuscano ET, Tuscano JM. PMID: 24418298.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    63. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013 Aug; 27(4):293-304. Sullivan-Chang L, O'Donnell RT, Tuscano JM. PMID: 23696252.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    64. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013 Sep; 162(5):639-47. Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. PMID: 23834234.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    65. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 Dec 01; 1(9):1469-1475. Kato J, O'Donnell RT, Abuhay M, Tuscano JM. PMID: 23264893; PMCID: PMC3525602.
      View in: PubMed   Mentions: 7     Fields:    
    66. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20; 31(6):684-91. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. PMID: 23182987; PMCID: PMC3574266.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCTClinical Trials
    67. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013 Jan; 37(1):83-8. Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM. PMID: 23040543.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    68. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. PMID: 22986740.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    69. Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 2012 Jun 04; 9(6):1727-35. Kato J, Li Y, Xiao K, Lee JS, Luo J, Tuscano JM, O'Donnell RT, Lam KS. PMID: 22530955; PMCID: PMC4560237.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    70. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol. 2011 Dec 01; 4:49. Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. PMID: 22128838; PMCID: PMC3287147.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    71. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia. 2011 Oct; 25(10):1543-7. Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM. PMID: 21625235; PMCID: PMC3165084.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    72. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. PMID: 21517811; PMCID: PMC3272081.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    73. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011 Jun; 60(6):771-80. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. PMID: 21347809; PMCID: PMC3098984.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    74. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010 May 15; 16(10):2760-8. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. PMID: 20460479.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    75. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology. 2009 Dec; 50(6):1893-903. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME. PMID: 19877182; PMCID: PMC4130556.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    76. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev. 2010 Mar; 9(5):A335-41. Sands J, Tuscano JM. PMID: 19914405.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    77. B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics. 2009; 3:225-32. Tuscano JM, Sands J. PMID: 19707411; PMCID: PMC2726057.
      View in: PubMed   Mentions: 1  
    78. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother. 2009 Dec; 58(12):2051-8. O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. PMID: 19437017; PMCID: PMC2749165.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    79. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom. 2009 May; 76(3):159-68. Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J. PMID: 18823005; PMCID: PMC4425447.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    80. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs. 2010 Jun; 28(3):260-7. O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. PMID: 19306119; PMCID: PMC2850518.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    81. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. 2009 Oct; 58(10):1715-22. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. PMID: 19294384; PMCID: PMC11030258.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    82. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009 May; 145(3):344-9. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. PMID: 19245430.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    83. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 2009 Jul; 33(7):964-9. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. PMID: 19237192.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    84. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts. Mol Imaging Biol. 2009 Mar-Apr; 11(2):79-87. Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. PMID: 18949521.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    85. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20; 26(30):4952-7. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. PMID: 18606983.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansCTClinical Trials
    86. Multiple myeloma: epidemiology and therapeutic options. Manag Care. 2008 Jul; 17(7 Suppl 6):9-15. Tuscano JM. PMID: 19093334.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. Nondestructive identification of individual leukemia cells by laser trapping Raman spectroscopy. Anal Chem. 2008 Mar 15; 80(6):2180-7. Chan JW, Taylor DS, Lane SM, Zwerdling T, Tuscano J, Huser T. PMID: 18260656.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    88. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol. 2007 Nov; 171(5):1538-48. Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, Tuscano J, Matsumura F. PMID: 17823287; PMCID: PMC2043515.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    89. Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays. Mol Cell Proteomics. 2006 Apr; 5(4):758-68. Khan IH, Mendoza S, Rhyne P, Ziman M, Tuscano J, Eisinger D, Kung HJ, Luciw PA. PMID: 16369048.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    90. B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis. Hematology. 2005 Dec; 10(6):521-7. Tuscano JM, Martin S, Song K, Wun T. PMID: 16321818.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    91. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005 Nov; 32(11):2109-15. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. PMID: 16265687.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    92. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. PMID: 16115934.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCTClinical Trials
    93. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    94. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res. 2004 Feb; 28(2):179-90. Wun T, McKnight H, Tuscano JM. PMID: 14654083.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    95. Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. Acc Chem Res. 2003 Jun; 36(6):370-7. Lam KS, Liu R, Miyamoto S, Lehman AL, Tuscano JM. PMID: 12809522.
      View in: PubMed   Mentions: 31     Fields:    Translation:Cells
    96. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev. 2003 Mar; 2(2):101-8. Tuscano JM, Harris GS, Tedder TF. PMID: 12848966.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    97. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. PMID: 12511412.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    98. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002 Dec; 42(12):1567-72. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. PMID: 12473136.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    99. Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect. J Autoimmun. 2002 Nov; 19(3):103-9. Tuscano JM, Hsu TC, McKnight H, Ansari AA, Gershwin ME. PMID: 12419280.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    100. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol. 2002 Nov; 76(4):360-4. Law L, Tuscano J, Wun T, Ahlberg K, Richman C. PMID: 12463601.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol. 2002 Jul; 70(3):191-4. Wang SE, Lara PN, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T. PMID: 12111764.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    102. Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. Ann Hematol. 2002 Feb; 81(2):108-10. Martel L, Reddy K, Greco M, Tuscano M, Richman M, Wun T. PMID: 11907793.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    103. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001 Jul 01; 98(1):41-8. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. PMID: 11418461.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    104. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 256     Fields:    Translation:Humans
    105. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma. BioDrugs. 2001; 15(3):151-62. Wun T, Kwon DS, Tuscano JM. PMID: 11437681.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    106. Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation. Blood. 2000 Feb 01; 95(3):776-82. Shi CS, Tuscano J, Kehrl JH. PMID: 10648385.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    107. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood. 1999 Aug 15; 94(4):1382-92. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. PMID: 10438726.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    108. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood. 1999 Feb 15; 93(4):1338-45. Shi CS, Tuscano JM, Witte ON, Kehrl JH. PMID: 9949177.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    109. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol. 1998 Aug; 10(4):287-97. Sato S, Tuscano JM, Inaoki M, Tedder TF. PMID: 9695185.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    110. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997; 15:481-504. Tedder TF, Tuscano J, Sato S, Kehrl JH. PMID: 9143697.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    111. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods. 1997 Jan; 11(1):128-32. Rieckmann P, Tuscano JM, Kehrl JH. PMID: 8990098.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    112. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood. 1996 Aug 15; 88(4):1359-64. Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH. PMID: 8695854.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    113. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood. 1996 Jun 01; 87(11):4723-30. Tuscano J, Engel P, Tedder TF, Kehrl JH. PMID: 8639842.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    114. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol. 1996 Jun; 26(6):1246-52. Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH. PMID: 8647200.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    115. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol. 1995 Dec 01; 155(11):5220-6. Tortolani PJ, Lal BK, Riva A, Johnston JA, Chen YQ, Reaman GH, Beckwith M, Longo D, Ortaldo JR, Bhatia K, McGrath I, Kehrl J, Tuscano J, McVicar DW, O'Shea JJ. PMID: 7594533.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    116. A novel human homeobox gene distantly related to proboscipedia is expressed in lymphoid and pancreatic tissues. J Biol Chem. 1994 Aug 05; 269(31):19968-75. Harrison KA, Druey KM, Deguchi Y, Tuscano JM, Kehrl JH. PMID: 7914194.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    Joseph's Networks
    Concepts (486)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (81)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-12-gbedcc43d on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California